Editorial for Nordic Journal of Psychiatry

References

• Bresee LC, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophrenia Research 2010;117(1):75–82.
   Google Scholar
• de Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller, HJ. Cardiovascular disease and diabetes is people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 2009;24:412–24.
   PubMed Web of Science ®Google Scholar
• de Hert M, Schreurs V, Vancamfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8(1):15–22.
   Google Scholar
• Fleischhacker WW, Cetkovich-Bakmas M, de Hert M, Hennekens CH, Lambert M, Leucht S, . Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges. Journal of Clinical Psychiatry 2008;69:514–19.
   PubMed Web of Science ®Google Scholar
• Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica 2007;116(5):317–33.
   Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19:1–93.
   PubMed Web of Science ®Google Scholar
• Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- versus second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 2008;192(6):406–11.
   Google Scholar
• Vancampfort D, Knapen J, Probst M, van Winkel R, Deckx S, Maurissen K, . Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Research 2010;177(3):271–9.
   Google Scholar
• Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950–2005. Schizophrenia Research 2008;98(1–3):287–94.
   Google Scholar
• Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 2006;3:A42.
   PubMedGoogle Scholar
• de Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research 2010;117(1):68–74.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. Journal of Clinical Psychiatry 2007;68(6):899–907.
   Google Scholar
• Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Archives of General psychiatry 2007; 64(2):242–49.
   Google Scholar
• Ösby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research 2000;45(1–2):21–8.
   PubMed Web of Science ®Google Scholar
• Ösby U, Correia N, Brandt L, Ekbom A, Sparen P. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. BMJ 2000;321(7259):483–4.
   Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General psychiatry 2007; 64:1123–31.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374(9690), 620–7.
   PubMed Web of Science ®Google Scholar
• Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophrenia Research 2009;113(1):1–11.
   Google Scholar
• de Hert M, Vancampfort D, Correll C, Mercken V, Peuskens J, Sweers K, . A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia. British Journal of Psychiatry 2010; submitted.
   Google Scholar
• Gothefors D, Adolfsson R, Attvall S, Erlinge D, Jarbin H, Lindström K, . Swedish Clinical Guidelines Prevention and management of metabolic risk in patients with severe psychiatric disorders. Nordic Journal of Psychiatry. 2010;64:294–302.
   PubMed Web of Science ®Google Scholar
• AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Quality and Safety in Health Care 2003;12(1):18–23.
   Google Scholar
• Institute of Medicine. Guidelines for clinical practice: from development to use. Washington DC: National Academy Press; 1992.
   Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, . Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010;36(1):71–93.
   Google Scholar
• Pincus HA. From PORT to policy to patient outcomes: crossing the quality chasm. Schizophrenia Bulletin 2010;36(1):109–11.
   Google Scholar
• Barnes TR, Paton C, Cavanagh MR, Hancock E, Taylor DM. UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bulletin 2007;33(6):1397–403.
   Google Scholar
• Buckley PF, Miller DD, Singer B. Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research 2005;79:281–88.
   PubMed Web of Science ®Google Scholar
• Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. American Journal of Psychiatry 2009;166(3):345–53.
   Google Scholar
• Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR, Rahnavard F. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. Journal of the American Pharmacists Association 2008;48(3):393–400.
   Google Scholar
• Morrato EH, Newcomer JW, Allen RR, Valuck R. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. Journal of Clinical Psychiatry 2008;69(2):316–22.
   Google Scholar
• Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32(6):1037–42.
   Google Scholar
• Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, . Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of General psychiatry 2010;67(1):17–24.
   Google Scholar
• Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, . Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatric and Adolescent Medicine 2010;164(4):344–51.
   Google Scholar
• Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 2006;86(1–3):15–22.
   Google Scholar
• Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey. Journal of Clinical Psychopharmacology 2004;24:1–6.
   Web of Science ®Google Scholar
• Johnsen E, Gjestad R, Kroken R, Mellesdal L, Løberg EM, Jørgensen H. Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study. Nordic Journal of Psychiatry. 2010;epub ahead of print.
   Google Scholar